Adagene (ADAG) Accounts Payables (2019 - 2026)
Adagene (ADAG) posted quarterly Accounts Payables of $2884.5 billion for Q4 2025, down 32.0% year-over-year from $4241.8 billion in Q4 2024, and up 79545669.8% quarter-over-quarter from $3.6 million in Q2 2025.
Adagene (ADAG) Accounts Payables (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Accounts Payables for 7 consecutive years, with $2884.5 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables fell 32.0% year-over-year to $2884.5 billion; the TTM figure through Dec 2025 stood at $2884.5 billion (down 32.0% YoY), while the FY2025 annual figure was $2884.5 billion, down 32.0% from the prior year.
- Accounts Payables rose to $2884.5 billion in Q4 2025 per ADAG's latest filing, from $3.6 million in the prior quarter.
- Across five years, Accounts Payables topped out at $4665.9 billion in Q2 2022 and bottomed at $2.8 million in Q2 2021.
- Historically, Accounts Payables has averaged $2303.6 billion across 5 years, with a median of $2989.1 billion in 2023.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 164640507.15% — and 2024, when it sank 100.0%.
- Adagene's Accounts Payables stood at $3.3 million in 2021, then surged by 110371631.82% to $3666.1 billion in 2022, then slipped by 15.61% to $3093.8 billion in 2023, then surged by 37.11% to $4241.8 billion in 2024, then sank by 32.0% to $2884.5 billion in 2025.
- Business Quant data shows ADAG's Accounts Payables at $2884.5 billion in Q4 2025, $3.6 million in Q2 2025, and $4241.8 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 15.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.54 Mn |
| Dec 31, 2025 | 2,884.51 Bn |
| Jun 30, 2025 | 3.63 Mn |
| Dec 31, 2024 | 4,241.77 Bn |
| Jun 30, 2024 | 3.37 Mn |
| Dec 31, 2023 | 3,093.75 Bn |
| Jun 30, 2023 | 4,483.78 Bn |
| Dec 31, 2022 | 3,666.12 Bn |
| Jun 30, 2022 | 4,665.87 Bn |
| Dec 31, 2021 | 3.32 Mn |
| Jun 30, 2021 | 2.83 Mn |
| Dec 31, 2020 | 1.81 Mn |
| Dec 31, 2019 | 712,714.00 |